Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bora Completes Upsher-Smith Takeover

Taiwanese Firm Gains First US Manufacturing Facilities After Acquiring Firm From Sawai

Executive Summary

Bora Pharmaceuticals has completed its takeover of Upsher-Smith from Sawai, with the acquisition opening up new US opportunities for the Taiwanese company including providing the firm with its first US manufacturing sites.

You may also be interested in...



Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.

Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Boehringer Ingelheim’s decision to cut sales staff for its Cyltezo US biosimilar rival to Humira not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the struggles for Humira biosimilars more widely.

Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel